Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments
Open Access
- 6 August 2013
- journal article
- review article
- Published by Springer Nature in Inflammopharmacology
- Vol. 21 (5) , 339-363
Abstract
Prostate cancer (PCa) has a high propensity for metastasis to bone. Despite the availability of multiple treatment options for relief of PCa-induced bone pain (PCIBP), satisfactory relief of intractable pain in patients with advanced bony metastases is challenging for the clinicians because currently available analgesic drugs are often limited by poor efficacy and/or dose-limiting side effects. Rodent models developed in the past decade show that the pathobiology of PCIBP comprises elements of inflammatory, neuropathic and ischemic pain arising from ectopic sprouting and sensitization of sensory nerve fibres within PCa-invaded bones. In addition, at the cellular level, PCIBP is underpinned by dynamic cross talk between metastatic PCa cells, cellular components of the bone matrix, factors associated with the bone microenvironment as well as peripheral components of the somatosensory system. These insights are aligned with the clinical management of PCIBP involving use of a multimodal treatment approach comprising analgesic agents (opioids, NSAIDs), radiotherapy, radioisotopes, cancer chemotherapy agents and bisphosphonates. However, a major drawback of most rodent models of PCIBP is their short-term applicability due to ethical concerns. Thus, it has been difficult to gain insight into the mal(adaptive) neuroplastic changes occurring at multiple levels of the somatosensory system that likely contribute to intractable pain at the advanced stages of metastatic disease. Specifically, the functional responsiveness of noxious circuitry as well as the neurochemical signature of a broad array of pro-hyperalgesic mediators in the dorsal root ganglia and spinal cord of rodent models of PCIBP is relatively poorly characterized. Hence, recent work from our laboratory to develop a protocol for an optimized rat model of PCIBP will enable these knowledge gaps to be addressed as well as identification of novel targets for drug discovery programs aimed at producing new analgesics for the improved relief of intractable PCIBP.Keywords
This publication has 269 references indexed in Scilit:
- Steps in prostate cancer progression that lead to bone metastasisInternational Journal of Cancer, 2011
- Treatment and prevention of bone complications from prostate cancerBone, 2011
- Metastatic bone disease: Role of transcription factors and future targetsBone, 2011
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Sclerostin: Current Knowledge and Future PerspectivesCalcified Tissue International, 2010
- A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancerInvestigational New Drugs, 2009
- Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancerCancer, 2008
- Dickkopf‐1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasisThe Prostate, 2008
- Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastasesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- A “class action” against the microenvironment: do cancer cells cooperate in metastasis?Cancer and Metastasis Reviews, 2007